ArticlePediatric blood & cancer2014
Challenges for children and adolescents with cancer in Europe: the SIOP-Europe agenda.
Article in Pediatric blood & cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Systematic review of phase-I/II trials enrolling refractory and recurrent Ewing sarcoma: Actual knowledge and future directions to optimize the research.Cancer medicine · 2021Pooled it
- Why children's research assent matters: Exploring three dimensions of autonomy.Nursing ethics · 2026Article
- Article
- Paediatric Phase I/II Clinical Trial Assessments Under the New EU Clinical Trial Regulation: A Descriptive Analysis.Pharmaceutical medicine · 2026Article
- Paediatric very rare tumours registration and management in European countries with low health expenditure average rates.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Ethical concerns when recruiting children with cancer for research: Swedish healthcare professionals' perceptions and experiences.BMC medical ethics · 2023Article
- Functional outcomes at PICU discharge in hemato-oncology children at a tertiary oncology center in Hong Kong.International journal of clinical oncology · 2022Observational
- Review of the genomic landscape of common pediatric CNS tumors and how data sharing will continue to shape this landscape in the future.Molecular biology reports · 2021Review
- Treatment of rhabdomyosarcoma in children and adolescent from four low health expenditures average rates countries.Radiology and oncology · 2020Article
- Improvement in childhood cancer survival in Lithuania over three decades.Acta medica Lituanic · 2020Article
- Use case driven evaluation of open databases for pediatric cancer research.BioData mining · 2019Article
- Incidence and survival time trends for Spanish children and adolescents with leukaemia from 1983 to 2007.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017Article
- Survivorship after childhood cancer: PanCare: a European Network to promote optimal long-term care.European journal of cancer (Oxford, England : 1990) · 2015Article
- Drug discovery in paediatric oncology: roadblocks to progress.Nature reviews. Clinical oncology · 2014Review
- Commentary on: "The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma." By Burzynski et al.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 13 institutions in 11 countries.
Funding
Abstract
In Europe, 6,000 young people die of cancer yearly, the commonest disease causing death beyond the age of 1 year. In addition, 300,000-500,000 European citizens are survivors of a childhood cancer and up to 30% of them have severe long-term sequelae of their treatment. Increasing both cure and quality of cure are the two goals of the European paediatric haematology/oncology community. SIOPE coordinates and facilitates research, care and training which are implemented by the 18 European study groups and 23 national paediatric haematology/oncology societies. SIOPE is the European branch of the International Society of Paediatric Oncology and one of the six founding members of the European Cancer Organisation. SIOPE is preparing its strategic agenda to assure long-term sustainability of clinical and translational research in paediatric malignancies over the next 15 years. SIOPE tackles the issues of equal access to standard care and research across Europe and improvement of long term follow up. SIOPE defined a comprehensive syllabus for training European specialists. A strong partnership with parent, patient and survivor organisations is being developed to successfully achieve the goals of this patient-centred agenda. SIOPE is advocating in the field of EU policies, such as the Clinical Trials Regulation and the Paediatric Medicine Regulation, to warrant that the voice of young people is heard and their needs adequately addressed. SIOPE and the European community are entirely committed to the global agenda against childhood cancers to overcome the challenges to increasing both cure and quality of cure of young people with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.